The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and Cisplatin or Pemetrexed Inhibit Mesothelioma Cells In Vitro

Malignant pleural mesothelioma (MPM) is a rare thoracic solid tumor cancer that has been strongly linked to asbestos exposure. It has a long latency period of at least 20-30 years following exposure, and global incidence is still increasing in countries where asbestos is still in use. Surgical resection for patients with early stage MPM is considered standard therapy and radiation therapy offers only palliative benefit. For patients with advanced disease, combination chemotherapy with Cisplatin and Pemetrexed results in improvement in survival and quality of life, thus constituting the “standard of care”.

Source: International Journal of Radiation Oncology * Biology * Physics - April 8, 2019 Category: Radiology Authors: M. Munster, R.S. Schneiderman, Y. Porat, T. Voloshin, S. Davidi, A. Shteingauz, N. Kaynan, E. Zeevi, K. Gotlib, M. Giladi, E. Kirson, U. Weinberg, A. Kinzel, Y. Palti Source Type: research